Biological Dynamics, an early detection disease management company, expands leadership
/Diagnostics industry veterans Mike Aicher, Mike Nall, and Mike Russell have joined Biological Dynamics.
Read MoreBiological Dynamics to Participate in Key Life Science and Healthcare Meetings
/Biological Dynamics, Inc. announces participation in a series of global events to discuss liquid biopsy industry trends and challenges, and to review new early-stage cancer detection data based on our company’s proprietary platform technology. Events include:
April 5, 2022: Chief Medical Officer Summit 360 – Fireside Chat with Dr. Paul Billings, CEO and Director
April 8 – 13, 2022: AACR (American Association for Cancer Research) Annual Meeting – Lung cancer and Pancreatic cancer data
May 16, 2022: AUA (American Urological Association) Annual Meeting – Bladder cancer data
May 25 – 29, 2022: ISEV (International Society for Extracellular Vesicles) Annual Meeting – Pancreatic, Ovarian, and Bladder cancer data
June 21, 2022: Nephron Liquid Biopsy Innovation Symposium
June 30, 2022: PMWC (Precision Medicine World Conference) – Early-stage cancer data
Biological Dynamics Study Demonstrates Detection of Early-Stage Cancers
/Biological Dynamics, Inc. announces the publication of its study, Early-Stage Multi-Cancer Detection Using an Extracellular Vesicle Protein-Based Blood Test, published in Nature Communications Medicine. The test correctly identified 71 percent of stage 1 cancers in a combined cohort of pancreatic, ovarian, and bladder cancers with pancreatic stage 1 cancer detection at 96%.
“The results are remarkable and highlight exosomal protein markers as a viable candidate for early-stage cancer detection,” said Scott Lippman, M.D., co-senior author of this report and Director of UC San Diego Moores Cancer Center. “Specifically, pancreatic cancer is notoriously difficult to detect at an early stage, when surgery, the only curative therapy, is possible. Biological Dynamics’ assay is demonstrating the potential for early-stage cancer detection to be included in the standard of care."
Read MorePrecision Medicine Expert Dr. Paul Billings Rejoins Biological Dynamics, Inc. as Chief Executive Officer and Director
/Biological Dynamics, Inc., a novel multiomic test company focused on detecting diseases at their earliest stages, announced the return of Paul Billings, MD, PhD, FACP, FACMGG to the company as Chief Executive Officer and Director. Previously, Dr. Billings has served in Advisor, Director, and Board Chairman roles before leaving to become Chief Medical Officer and Senior Vice President of Medical Affairs at Natera, Inc.
Read MoreFDA Grants Breakthrough Device Designation for Biological Dynamics’ Early-stage Pancreatic Cancer Detection Test
/Biological Dynamics, Inc., a multiomics liquid biopsy company focused on detecting cancers at the earliest stages, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its liquid biopsy assay, Exo-PDAC. The test is designed to provide early detection for pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and lethal forms of cancer worldwide.
Read MoreBiological Dynamics to Present at UBS Genomics 2.0 and MedTech Innovations Summit
/Biological Dynamics, Inc., a next-generation liquid biopsy company focused on detecting cancers at the earliest stages, will present at the UBS Genomics 2.0 and MedTech Innovations Summit in Laguna Beach, California. The panel discussion takes place on Tuesday, August 10, 2021 at 7:00 p.m. PT.
Kevin Han, CFO, will be joined by Dr. Dave Hoon, Professor and Director, Translational Molecular Medicine and Genome Sequencing at Saint John's Cancer Institute to collaborate in a panel discussion, Emerging Players in Liquid Biopsy, focused on Biological Dynamics’ patented technology that empowers cancer detection at the earliest stages.
Read MoreBiological Dynamics to Participate in the Nephron Research Liquid Biopsy Innovation Symposium
/CEO Raj Krishnan, Ph.D. and CFO Kevin Han, will be joined by Dr. Dave Hoon, Professor and Director, Translational Molecular Medicine and Genome Sequencing at Saint John's Cancer Institute to collaborate in a panel discussion, Novel Approaches for Early Cancer Detection, on Wednesday, June 16, 2021, at 12:10 p.m. ET / 9:10 a.m. PT.
Biological Dynamics will discuss a transformative approach to cancer screening using a proprietary platform that enables the isolation and evaluation of non-DNA biomarkers, such as exosomes, exo-proteins, and surfaceomes. The company will also discuss how the access to these differentiated biomarkers from blood can empower cancer detection at the earliest stages.
Read MoreBiological Dynamics to Present at the 39th Annual J.P. Morgan Healthcare Conference
/Biological Dynamics, Inc., a healthcare company committed to improving global health outcomes by detecting diseases at an early stage, will present at the 39th Annual J.P. Morgan Healthcare Conference. CEO Raj Krishnan, Ph.D. and CFO Kevin Han, will provide an overview of the company and host a Q&A on Tuesday, January 12, 2021, at 5:30 p.m. ET.
Read MoreBiological Dynamics Appoints Kevin Han as New Chief Financial Officer
/Biological Dynamics announced it has named Kevin Han as its new Chief Financial Officer, bringing a depth of expertise in capital markets and investor relations and a breadth of healthcare industry knowledge. Mr. Han, a veteran life science industry investor, joins Biological Dynamics following an accomplished career in equity research, investment management, and investor relations, specifically focused on the life science tools, diagnostics, and medical technology sectors.
Read MoreBiological Dynamics Expands Biomarkers Research Into Alzheimer’s With Funding From Alzheimer’s Drug Discovery Foundation (ADDF)
/Biological Dynamics receives funding from the Alzheimer’s Drug Discovery Foundation to use its proprietary Verita™ platform to develop a portfolio of assays for detection and quantification of blood-based biomarkers associated with AD and other neurodegenerative conditions.
Read MoreBiological Dynamics Initiates New Phase of Next Generation Tuberculosis Test Development
/Biological Dynamics, Inc., an innovative diagnostic company committed to improving global health, today announced a supplemental grant to support efforts to optimize and evaluate the performance of a novel TB test currently in development. The funding is from the Bill & Melinda Gates Foundation.
Read MoreBiological Dynamics Enters Collaboration to Advance Access to Novel Diagnostic Solutions to Life Science Customers
/Biological Dynamics, Inc., an innovative diagnostic company committed to improving global health, today announced it has been accepted to Microsoft's One Commercial Partner (OCP) program. The company will use the comprehensive development solutions available to OCP partners to develop and establish a research service delivery model, to provide Microsoft's Life Science partners and customers access to cutting edge molecular diagnostic solutions powered by Biological Dynamics' novel isolation platform.
Read MoreBiological Dynamics Receives Grant Award Funding to Advance Point-of-Care Molecular Diagnostic Platform
/Biological Dynamics, Inc., an innovative diagnostic company committed to improving global health outcomes, today announced a new grant award from the Bill & Melinda Gates Foundation.
Read MoreBiological Dynamics Selected as Winner of CONNECT’s 2018 Most Innovative New Product Award
/
SAN DIEGO--(BUSINESS WIRE)--Biological Dynamics, a company committed to improving global health outcomes by empowering global communities with accessible cancer diagnostics, today announced that its OmniVerita™ system has been selected as the winner of CONNECT’s Most Innovative New Product Award in the Life Science Products, Clinical Stage category.
Read MoreBiological Dynamics Awarded Grant to Develop the Next Generation of Smartphone-Enabled Tuberculosis Tests
/SAN DIEGO--(BUSINESS WIRE)--Today, Biological Dynamics announced it has received a grant from the Bill & Melinda Gates Foundation to help address the pressing need of reducing the burden of tuberculosis (TB) in resource-poor settings.
Read MoreBiological Dynamics Appoints Irwin M. Jacobs as Chairman of the Board
/SAN DIEGO -Biological Dynamics, a company committed to improving global health outcomes by empowering global communities with accessible cancer diagnostics, today announced the appointment of Dr. Irwin M. Jacobs as Chairman of the Board. Dr. Jacobs is founding Chairman and CEO Emeritus of Qualcomm and Chairman Emeritus of the Salk Institute for Biological Studies.
Read MoreBiological Dynamics and the OHSU Knight Cancer Institute Announce Cancer Diagnostic Research Collaboration
/SAN DIEGO and PORTLAND, Oregon, September 28, 2017 -- Biological Dynamics, Inc., a developer of innovative oncology-focused molecular diagnostic products, and the Knight Cancer Institute at Oregon Health & Science University (OHSU), a national leader in translational oncology research, have initiated a collaboration to advance early cancer detection. The research will take place at the OHSU Cancer Early Detection Advanced Research (CEDAR) Center in Portland, with Biological Dynamics providing CEDAR Center researchers with early technology access to its NanoVerita™ and ExoVerita™ platforms.
Read MoreJohn L. "Kip" Miller Joins Biological Dynamics’ Board of Directors
/Biological Dynamics Inc., a privately held molecular diagnostics company and a pioneer in the field of Alternating Current Electrokinetics (ACE)-based diagnostics, announces the appointment of John L. “Kip” Miller to the Board of Directors.
Read MoreBiological Dynamics Appoints Paul Billings, MD, PhD to Board of Directors
/Biological Dynamics Inc., a privately held molecular diagnostics company and a pioneer in the field of Alternating Current Electrokinetics (ACE) - based diagnostics, announces the appointment of Paul Richard Billings, MD, PhD, FACP, FACMG to the Company’s Board of Directors.
Read MoreBiological Dynamics Announces $26.8M Series C Financing
/Biological Dynamics, Inc., a molecular diagnostics company, announced today that it has completed a $26.8M round of financing.
Read More